ClinicalTrials.gg
Active, not recruitingNCT06047457E-BEONDUpdated Sep 4, 2026

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

A Phase 3 interventional study of Botulinum toxin type A and Botulinum toxin type A in Episodic Migraine, sponsored by Ipsen. Active, not recruiting at 105 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Ipsen · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
751
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing botulinum toxin type A in Migraine Disorders — 6 open to participants now, 10 under way, 5 of them phase 3. botulinum toxin type A · Migraine Disorders.

Enrollment
6th of 39
751 · median 70
Started
2023
with 2 others
Phase 3
13 of 39
1 open now
Registered
32nd of 39
by date
Lead sponsor
3 of 39
Ipsen

Among the 39 studies testing botulinum toxin type A in Migraine Disorders, this one is the 6th largest by enrollment, is one of 3 that started in 2023, is one of 13 in phase 3, and was the 32nd registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 39 studies testing botulinum toxin type A in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About botulinum toxin type A

botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing botulinum toxin type A in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine.

A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound.

Episodic Migraine is defined as having less than 15 days of headache a month with at least 6 days with migraine headaches.

Migraines are caused by a series of events which cause the brain to get stimulated / activated, which results in the release of chemicals that cause pain.

Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers.

The study will consist of 3 periods:

  1. A 'screening period' of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit.
  2. A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders.

    The injections will contain either a dose "A" or a dose ''B'' of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied).

    Participants will make 4 visits to the clinic in person and have 4 remote (online) visits.

  3. A second Treatment Phase of 24 weeks (extension phase). At Week 24 and at Week 36, all participants will get Dysport® (dose "A" or dose "B").

There will be 3 in person visits and 4 remote visits.

Participants will need to complete an e-diary and questionnaires throughout the study.

Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded.

The total study duration for a participant will be up to 60 weeks (approx. 14 months).

03

Conditions studied

  • Episodic Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be ≥18 years of age inclusive, at the time of signing the and privacy/data protection documentation.
  • Participant has a diagnosis for more than 12 months, prior to screening visit, of migraine with aura or migraine without aura according to the International Classification of Headache Disorders definition and diagnostic criteria
  • Migraine onset occurred when participant was \<50 years of age.
  • Has baseline number of monthly headache days (MHD) of \<15 and baseline number of monthly migraine days (MMD) of ≥6, using eDiary data collected during the 4 weeks nearest to randomisation on Day 1 (but prior to randomisation).
  • Has baseline number of valid diary days ≥22 days collected during the 4 weeks nearest to randomisation on Day 1.
  • Participant must have previously used, or is currently using, preventive treatment for migraine (pharmacological) (i.e. non-naïve) prior to start of screening eDiary

Exclusion criteria

Exclusion Criteria :

  • History or current diagnosis of migraine with brainstem aura, retinal migraine, complications of migraine, tension-type headache, trigeminal autonomic cephalalgias, hypnic headache, hemicrania continua, or new daily persistent headache.
  • Headache attributed to another disorder (e.g. secondary headaches), except medication overuse headache, which is permitted.
  • Use of any of the following medications in the specified timeframe prior to start of the screening daily headache eDiary:

    a. Within 24 weeks

  • i. Botulinum toxin for migraine (or for any other medical/aesthetic reason within 16 weeks)

    b. Within 12 weeks

  • i. CGRP antagonists (monoclonal antibody or gepant) for preventive treatment of migraine (acute treatment of headache/migraine with a gepant is permitted, but limited to no more than 6 days per month (i.e. 6 days per each 4-week period with gepant intake))
  • ii. Cannabinol or other types of cannabinoids

    c. Within 4 weeks

  • i. Anaesthetic or injection in any region targeted for injection with study intervention
  • ii. Use of medical device to treat migraine (e.g. non-invasive neuromodulation therapies such as nerve stimulation (gammaCore), transcranial magnetic stimulation (cephaly), external trigeminal nerve stimulation, transcutaneous electrical nerve stimulation, and peripheral neuroelectrical stimulation)
  • iii. Other interventions for migraine assessed to interfere with study evaluations (e.g. acupuncture in head and neck region, cranial traction, nociceptive trigeminal inhibition, occipital nerve block treatments, and dental splints for headache) iv. Use of opioids or barbiturates for more than 2 days/month.

Note: participants are permitted to take one concomitant migraine preventative treatment (not listed above); however, the dose of this medication should be stable for ≥3 months before start of the screening eDiary.

  • Known history of treatment failure to more than four medications prescribed for the prevention of migraine (two of which have different mechanisms of action) or known history of treatment failure to botulinum toxin prescribed for the prevention of migraine
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
751 participants (actual)

Study arms

  • Experimental
    Dysport® dose "A"

    Participant will receive four treatment cycles, each separated by an interval of 12 weeks. Double-blind placebo-controlled (DBPC) Phase: Dysport® dose "A" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "A" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)

    Biological: Botulinum toxin type A

  • Experimental
    Dysport® dose "B"

    Participant will receive four treatment cycles, each separated by an interval of 12 weeks. DBPC Phase: Dysport® dose "B" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "B" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)

    Biological: Botulinum toxin type A

  • Placebo comparator
    Placebo - Dysport dose "A"

    Participant will receive four treatment cycles, each separated by an interval of 12 weeks. DBPC Phase: Placebo dose "A" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "A" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48).

    Other: Placebo · Biological: Botulinum toxin type A

  • Placebo comparator
    Placebo - Dysport dose "B"

    Participant will receive four treatment cycles, each separated by an interval of 12 weeks. DBPC Phase: Placebo dose "B" administered intramuscularly on Day 1 and Week 12. Extension Phase: Dysport® dose "B" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48).

    Other: Placebo · Biological: Botulinum toxin type A

Interventions

  • Dose "A" U /Injection (U/I) , Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections.

    Also known as: Dysport®

  • Dose "B" U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections.

    Also known as: Dysport®

  • OtherPlacebo

    "0" U/I, IM on Day 1 and Week 12 with a total of 2 injections.

  • Dose "A" U/I, IM on Week 24 and Week 36 with a total of 2 injections.

    Also known as: Dysport®

  • Dose "B" U/I, IM on Week 24 and Week 36 with a total of 2 injections.

    Also known as: Dysport®

06

What researchers measure

Primary outcomes

  1. Change from baseline in monthly migraine days (MMD)

    The monthly migraine days (MMD) is assessed by a daily eDiary, completed by the participant, to evaluate the efficacy of Dysport® compared to placebo.

    Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)

Secondary outcomes

  1. Change from baseline in MMD of ≥50%

    The monthly migraine days (MMD) is assessed by a daily eDiary.

    Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)

  2. Change from baseline in MMD of ≥75%

    The monthly migraine days (MMD) is assessed by a daily eDiary.

    Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)

  3. Cumulative number of MMD

    The cumulative number of monthly migraine days (MMD) is assessed by a daily eDiary.

    Time frame: From Day 1 to Week 24

  4. Change from baseline in MMD of moderate or severe intensity

    The intensity of MMD is assessed by a daily eDiary.

    Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)

  5. Change from baseline in the number of MMD over the last 12 weeks prior to Week 24

    The monthly migraine days (MMD) is assessed by a daily eDiary.

    Time frame: Weeks 13-24

  6. Change from baseline in monthly headache days (MHD) of moderate or severe intensity

    The intensity of monthly headache days (MHD) is assessed by a daily eDiary.

    Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)

  7. Change from baseline in MHD of moderate or severe intensity of ≥50%

    The intensity of monthly headache days (MHD) is assessed by a daily eDiary.

    Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)

  8. Change from baseline in MHD of moderate or severe intensity of ≥75%

    The intensity of monthly headache days (MHD) is assessed by a daily eDiary.

    Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)

  9. Cumulative number of MHD of moderate to severe intensity

    The cumulative number of monthly headache days (MHD) is assessed by a daily eDiary.

    Time frame: From Day 1 to Week 24

  10. Change from baseline in the number of days per month of acute migraine medication intake

    The acute migraine medication intake will be recorded in the daily eDiary Acute migraine medication is defined as triptan, ergotamine, gepant, or ditan

    Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)

  11. Headache medication overuser (yes, no)

    The headache medication overuse will be assessed by a concomitant medication log completed at each visit and acute medication taken to treat acute attack will be recorded in the daily eDiary. The headache medication overuse is defined as a participant with ≥10 days/month if ergotamine, triptan, gepant, ditan, opioid or combination analgesic, or ≥15 days/month if non-opioid analgesic (such as paracetamol, aspirin, NSAID)

    Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)

  12. Use of acute migraine medication (yes or no)

    The use of acute migraine medication will be recorded in the daily eDiary.

    Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)

  13. Patient's Global Impression of Change (PGIC) score

    The PGIC will be assessed by a questionnaire (7-point scale, score of 1 indicates very much improved and score of 7 indicates very much worse)

    Time frame: At Week 12 and Week 24

  14. PGIC score of grade ≥1 and ≥2

    The PGIC will be assessed by a questionnaire (7-point scale, score of 1 indicates very much improved and score of 7 indicates very much worse)

    Time frame: At Week 12 and Week 24

  15. Change from baseline in role function restrictive (RFR) domain of Migraine Specific Quality of Life Questionnaire (MSQ)

    The MSQ will be assessed by a questionnaire (Scores range from 0-100, higher scores indicate a better quality of life)

    Time frame: At Week 12 and Week 24

  16. Change from baseline in role function-preventive (RFP) domain of MSQ Questionnaire

    The MSQ will be assessed by a questionnaire (Scores range from 0-100, higher scores indicate a better quality of life)

    Time frame: At Week 12 and Week 24

  17. Change from baseline in emotional function (EF) domain of MSQ Questionnaire

    The MSQ will be assessed by a questionnaire (Scores range from 0-100, higher scores indicate a better quality of life)

    Time frame: At Week 12 and Week 24

  18. Change from baseline in total MSQ score

    The MSQ will be assessed by a questionnaire (Scores range from 0-100, higher scores indicate a better quality of life)

    Time frame: At Week 12 and Week 24

  19. Change in MSQ score to the minimally important change (MIC)

    The MSQ will be assessed by a questionnaire (Scores range from 0-100, higher scores indicate a better quality of life)

    Time frame: At Week 12 and Week 24

  20. Change from baseline in total 6-item Headache Impact Test (HIT-6) score

    The HIT-6 will be assessed by a questionnaire (scores range from 36-78 and higher scores indicate a greater impact of headache on subject's life)

    Time frame: At Week 12 and Week 24

  21. Change in total 6-item Headache Impact Text (HIT-6) score to the MIC thresholds

    The HIT-6 will be assessed by a questionnaire (scores range from 36-78 and higher scores indicate a greater impact of headache on subject's life)

    Time frame: At Week 12 and Week 24

  22. Change from baseline in Short Form 12 (SF-12) Questionnaire score

    The SF-12 will be assessed by a questionnaire (scores range from 0-100, with higher scores indicating better functioning)

    Time frame: At Week 12 and Week 24

  23. Change from baseline to Chronic migraine status

    Transition to Chronic migraine status will be assessed by the daily eDiary and defined as number of participants with ≥15 MHD and ≥8 MMD

    Time frame: At Week 24 (Week 21-24)

  24. Time to onset of effect

    Time to onset of effect is defined as the first time point post randomisation where MMD is reduced from baseline ≥50%

    Time frame: From first time point post randomisation to Week 24

  25. Incidence of Treatment emergent adverse event (TEAEs)

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to Week 24

  26. Percentage of Participants with clinically significant changes in vital signs

    Percentage of participants with clinically significant changes in vital signs will be reported. The clinical significance will be graded by the investigator.

    Time frame: From baseline up to Week 24

  27. Percentage of participants with clinically significant laboratory parameters (blood chemistry, haematology)

    Percentage of participants with clinically significant change in laboratory parameters (blood chemistry, hematology and coagulation) will be reported. The clinical significance will graded by the investigator.

    Time frame: From baseline up to Week 24

  28. Treatment-emergence of suicidal ideation/suicidal behaviour

    It will be assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) questionnaire that consists of 4 subscales: 1. Ideation severity subscale: questions answered yes/no, severity of ideation scored 1-5 with 5 being most severe 2. Intensity of ideation subscale : scores range from 2-25 with higher scores indicating more severe intensity of ideation. 3. Suicide behaviour subscale:4 types of suicidal behaviours are scored yes/no 4. Behaviour Lethality subscale: actual lethality/medical damage scores 0-5, with 5 being most severe (death) and potential lethality scores 0-2 with 2 being more potentially lethal.

    Time frame: From baseline up to Week 24

  29. Percentage of participants with binding antibodies to Dysport®

    Presence of binding antibodies will be assessed using a validated method of electrochemiluminescence assay (ECLA).

    Time frame: At Week 24

  30. Percentage of participants with neutralising antibodies to Dysport®

    It will be performed only for confirmed positive samples with ECLA (confirmation of the presence of binding antibodies). Presence of neutralizing antibodies will be assessed using a validated cell-based assay (CBA).

    Time frame: At Week 24

07

Study locations

105 sites

Showing the first 100 of 105 sites across 8 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jun 2026, 32 months.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 32 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Sep 21, 2023
StartActual
Sep 29, 2023
Primary completionActual
Jun 1, 2026
CompletionEst.
Nov 16, 2026
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06047457
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Sep 29, 2023
Primary completion
Jun 1, 2026
Completion
Nov 16, 2026 (estimated)
Last update
Sep 4, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion